Drug Profile
AM 92016
Latest Information Update: 12 Nov 2003
Price :
$50
*
At a glance
- Originator University of Strathclyde
- Class Class III antiarrhythmics
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 03 Sep 2000 Discontinued - Preclinical for Arrhythmias in United Kingdom (unspecified route)
- 03 Sep 1998 No-Development-Reported for Arrhythmias in United Kingdom (Unknown route)
- 14 Aug 1996 New profile